Lifecome Biochemistry Co Ltd
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, photovoltaic film products, etc.; veterinary drugs; and food preservatives. The company was founded in 2003 and is based in Pucheng, China.
Lifecome Biochemistry Co Ltd (002868) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.49 Billion CNY
Based on the latest financial reports, Lifecome Biochemistry Co Ltd (002868) has total liabilities worth CN¥1.49 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lifecome Biochemistry Co Ltd - Total Liabilities Trend (2012–2024)
This chart illustrates how Lifecome Biochemistry Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lifecome Biochemistry Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lifecome Biochemistry Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shandong Head Co Ltd
SHE:002810
|
China | CN¥1.75 Billion |
|
TTY Biopharm Co Ltd
TWO:4105
|
Taiwan | NT$3.74 Billion |
|
Xinjiang Baodi Mining Co. Ltd. A
SHG:601121
|
China | CN¥2.76 Billion |
|
Hagerty Inc
NYSE:HGTY
|
USA | $1.44 Billion |
|
Fuan Pharmaceutical Group Co
SHE:300194
|
China | CN¥1.51 Billion |
|
momo.com Inc
TW:8454
|
Taiwan | NT$17.26 Billion |
|
EcoRodovias Infraestrutura e Logística S.A
SA:ECOR3
|
Brazil | R$30.65 Billion |
Liability Composition Analysis (2012–2024)
This chart breaks down Lifecome Biochemistry Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -13.99 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lifecome Biochemistry Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lifecome Biochemistry Co Ltd (2012–2024)
The table below shows the annual total liabilities of Lifecome Biochemistry Co Ltd from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.52 Billion | -2.24% |
| 2023-12-31 | CN¥1.55 Billion | +142.12% |
| 2022-12-31 | CN¥640.56 Million | +19.42% |
| 2021-12-31 | CN¥536.38 Million | +164.80% |
| 2020-12-31 | CN¥202.56 Million | -12.52% |
| 2019-12-31 | CN¥231.55 Million | +273.18% |
| 2018-12-31 | CN¥62.05 Million | +2.45% |
| 2017-12-31 | CN¥60.56 Million | -39.02% |
| 2016-12-31 | CN¥99.32 Million | -35.31% |
| 2015-12-31 | CN¥153.54 Million | -22.93% |
| 2014-12-31 | CN¥199.22 Million | -12.03% |
| 2013-12-31 | CN¥226.45 Million | +5.37% |
| 2012-12-31 | CN¥214.92 Million | -- |